Gabriela M Almeida

Dr. Gabriela M Almeida

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal
+2
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
Raquel  T. LimaRaquel T. Lima
Raquel T. Lima
SBSara Busacca
Sara Busacca
GAGabriela M Almeida
Gabriela M Almeida
GGGiovanni Gaudino
Giovanni Gaudino
DFDean A. Fennell
Dean A. Fennell
MVM. Helena Vasconcelos
M. Helena Vasconcelos

1 February 2014 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
CDCecília Durães
Cecília Durães
GAGabriela M Almeida
Gabriela M Almeida
Raquel SerucaRaquel Seruca
Raquel Seruca
COCarla Oliveira
Carla Oliveira
FCFátima Carneiro
Fátima Carneiro

16 June 2017 in Pathobiology
Verified
Journal Article
Closed access
IGIrene Gullo
Irene Gullo
FCFátima Carneiro
Fátima Carneiro
COCarla Oliveira
Carla Oliveira
GAGabriela M Almeida
Gabriela M Almeida
Gastric cancer (GC) represents a global health concern. Despite advances in prevention, diagnosis, and therapy, GC is still the third leading cause of cancer mortality worldwide, with more than 720,000 estimated deaths in 2012. Overall survival for advanced disease is about 1 year, a dismal prognosis that is partly due to the high levels of biological heterogeneity found in GC. Indeed, GC is a highly heterogeneous disease from morphological and molecular standpoints. The numerous histological and molecular classifications currently available reflect such heterogeneity. Although recent high-throughput studies cluster the molecular data obtained into subgroups with clinical relevance, we still need a practical, prognostic, and predictive classification system, integrating morphological and molecular features, towards the identification of novel therapeutic targets. It is noteworthy that GC heterogeneity encompasses not only interpatient variability (intertumour heterogeneity), but also variations within the same tumour (intratumour heterogeneity). The latter encompasses spatial heterogeneity (in different tumour areas) and temporal heterogeneity (along progression from primary to recurrent and/or metastatic disease). In this review, we analyse the morphological, immunophenotypic, and molecular heterogeneity in GC as the basis for a better understanding of the disease, and discuss the practical implications for diagnostic pathology, prognostic evaluation, and precision therapy.

5 June 2006 in Oncogene
Verified
Journal Article
Open access
PDF file
RBR C Barber
R C Barber
PHP Hickenbotham
P Hickenbotham
THT Hatch
T Hatch
DKD Kelly
D Kelly
NTN Topchiy
N Topchiy
Yuri Evgenjevicth DubrovaYuri Evgenjevicth Dubrova
Yuri Evgenjevicth Dubrova
Mutation induction in directly exposed cells is currently regarded as the main component of the genetic risk of ionizing radiation for humans. However, recent data on the transgenerational increases in mutation rates in the offspring of irradiated parents indicate that the genetic risk could be greater than predicted previously. Here, we have analysed transgenerational changes in mutation rates and DNA damage in the germline and somatic tissues of non-exposed first-generation offspring of irradiated inbred male CBA/Ca and BALB/c mice. Mutation rates at an expanded simple tandem repeat DNA locus and a protein-coding gene (hprt) were significantly elevated in both the germline (sperm) and somatic tissues of all the offspring of irradiated males. The transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous DNA lesions (double- and single-strand breaks), measured by the phosphorylated form of histone H2AX (γ-H2AX) and alkaline Comet assays. Such remarkable transgenerational destabilization of the F1 genome may have important implications for cancer aetiology and genetic risk estimates. Our data also provide important clues on the still unknown mechanisms of radiation-induced genomic instability.

1 July 2013 in Current Drug Targets
Verified
Journal Article
Closed access
HSHugo Seca
Hugo Seca
Raquel  T. LimaRaquel T. Lima
Raquel T. Lima
VLVanessa Lopes-Rodrigues
Vanessa Lopes-Rodrigues
JGJose Guimaraes
Jose Guimaraes
GAGabriela M Almeida
Gabriela M Almeida
MVM. Helena Vasconcelos
M. Helena Vasconcelos
Overexpression of oncomiR-21 has been observed in most cancer types, such as leukemia. This miR has been implicated in a number of cellular processes, including chemoresistance, possibly by directly modulating the expression of several apoptotic related proteins. It was recently shown to directly target Bcl-2 mRNA and upregulate Bcl-2 protein expression. Nevertheless, the possible effect of miR-21 in autophagy has never been addressed. This study investigates the effects of targeting miR-21 with antimiRs on chronic myeloid leukemia cellular autophagy and on associated drug sensitivity. We observed that miR-21 downregulation decreased cellular viability and proliferation, although no changes to the normal cell cycle profile were observed. miR-21 downregulation also caused increased programmed cell death and a decrease in the expression levels of Bcl-2 protein, although PARP cleavage was not affected, indicating that apoptosis was not the relevant mechanism underlying the observed results. Treatment with antimiR-21 caused an increase in the autophagy related proteins Beclin-1, Vps34 and LC3-II. Accordingly, autophagic vacuoles were visualized both by monodansylcadaverine (MDC) and acridine orange (AO) staining and also by transmission electron microscopy (TEM). Additionally, miR-21 downregulation increased K562 and KYO-1 cellular sensitivity to etoposide or doxorubicin. This chemosensitivity was reverted by pre-treating cells with 3-MA, an autophagy inhibitor. Finally, serum starvation (an autophagy inducer) also increased sensitivity to these drugs, confirming that autophagy sensitized these cells to the effect of these drugs. To the best of our knowledge, this is the first description of autophagy induction via miR-21 targeting and its involvement in drug sensitivity.

1 October 2010 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
Josiana VazJosiana Vaz
Josiana Vaz
Sandrina A. HelenoSandrina A. Heleno
Sandrina A. Heleno
AMAnabela Lourenço Martins Martins
Anabela Lourenço Martins Martins
GAGabriela M Almeida
Gabriela M Almeida
MVM. Helena Vasconcelos
M. Helena Vasconcelos
Isabel FerreiraIsabel Ferreira
Isabel Ferreira